Neuphoria Therapeutics Inc. Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Neuphoria Therapeutics Inc. (NEUP) reported Deferred Tax Relating To Items Charged Or Credited Directly To Equity of -AUD 63.54 thousand for the 12-month period ending 2023-06-30, per its 20-F filed 2023-10-18.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2023-10-18
| Period end | Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month |
|---|---|
| 2023-06-30 | -63.54K AUD 20-F · filed 2023-10-18 |
| 2022-06-30 | -148.13K AUD 20-F · filed 2023-10-18 |
| 2021-06-30 | 173.61K AUD 20-F · filed 2022-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |